Orcilada, Chriszelle C.
HRN: 25-17-37 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/31/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/31/2024
06/06/2024
IV
145mg
Q12h
PCAP C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes